Elaborate on how to assess reasonable risk and dose selection based on preclinical data
|
|
- Adam Turner
- 1 years ago
- Views:
Transcription
1 May 7, 2014 Division of Dockets Management HFA-305 Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD Re: Docket No. FDA-2013-D-0576, Draft Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products To whom it may concern: On behalf of the (AACR), the oldest and largest scientific organization in the world dedicated to the prevention, detection and cure of cancer through research, education, communication and collaboration, we sincerely thank the U.S. Food and Drug Administration (FDA) for the opportunity to provide comments in response to the July 2013 draft guidance on Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products. The AACR applauds the FDA for developing detailed, forward-looking draft guidance on many of the key issues associated with early-phase trial design of cellular and gene therapy products. There are, however, a few areas in which we believe additional guidance would be beneficial. Specifically, the AACR requests the FDA to provide additional information with respect to assessment of reasonable risk, dose exploration and selection, safety and activity assessment, appropriate study population selection, establishment of stopping rules and integrating validation procedures for large scale production into early-phase study design. With these additions, we believe this document will encourage innovative approaches to early phase clinical trials of cellular and gene therapy products in oncology accelerating development of these novel therapies and create new hope for cancer patients worldwide. Elaborate on how to assess reasonable risk and dose selection based on preclinical data The Agency notes that the preclinical data generated for Cellular and Gene Therapy (CGT) products may not always be as informative as for small molecule pharmaceuticals, particularly since it usually is not feasible to conduct traditional preclinical pharmacokinetic (PK) studies with CGT products. The Agency suggests that Preclinical data generated from studies conducted in appropriate animal species and animal models of disease contribute to defining reasonable risk for the investigational CGT product. Since dose-selection is based on preclinical data and since risk
2 Page 2 determination will influence further conduct of these studies, we request that the agency elaborate and clarify what it means by reasonable risk. Further, if the agency could suggest alternate means of assessing risk or provide examples of preclinical studies that may aid in determining said risk and dose selection, it would aid sponsors in the design and conduct of these studies. Dose Selection The draft notes that in situations where there is uncertainty about the cell subset(s) responsible for the therapeutic or adverse effects, collecting data on various cell subsets in the final CT product, with a comparison of clinical outcomes associated with these different subsets, may help to identify the cell subsets most relevant to product safety and effectiveness. As this is a common problem associated with cellular-based therapies, it would be helpful to investigators if the agency could clarify what kind and level of data the agency would find acceptable. The draft suggests that when there is no previous human experience with a specific dose treating several patients simultaneously with that dose may pose an unreasonable risk. Therefore, staggering administration to limit the number of subjects exposed is suggested. This is especially suggested in the context of dose escalation such that the first few individuals may be staggered followed by staggered cohorts. With certain CT products each individual dose may vary (cellular expansion ex vivo, transduction efficiencies etc.). Therefore, it would be helpful if the agency could clarify how sponsors can establish a staggered dosing protocol while balancing dosing variabilities that may arise due to product characteristics. The agency notes that larger cohorts might be necessary to provide reasonable assurance of safety before escalating the dose of a product intended for a disease that is less serious and for which the tolerance for accepting risk might be lower. Smaller cohorts might be adequate for a product that is intended to treat a life-threatening disease where a greater potential benefit may justify a higher risk. Examples of what the agency considers large and small cohorts would be useful. This definition becomes especially relevant for autologous cell-based therapies and induced pluripotent stem cell therapies where a cohort is essentially the individual patient. Clarify Safety Assessment in early-phase CGT studies The Agency states that the primary objective for first-in-human studies should be safety evaluation. For CGT products this can involve assessment of safety related to specific dose levels as well as feasibility of administering certain doses as noted above. An additional consideration for CGT products is the risk that may be involved in administration of products. For example, CGT product administration may involve complicated procedures such as surgery. Therefore, it would be helpful to sponsors if the agency could clarify whether the route of product administration will impact the product s safety assessment by the agency. Additionally, it would help if the agency could address monitoring of potential long-term safety concerns. This is especially important in the case of CGT products wherein some adverse effects
3 Page 3 may not be evident during short-term monitoring. Sponsors could be invited to collect and archive post-treatment safety data from several early studies in order to develop long-term safety databases. It would be extremely helpful if the agency could provide some guidance and/or examples on what types of safety data and what level of detail should be collected in early phase studies. Early-phase studies usually involve small study populations. Therefore, having the flexibility to pool safety data from several different early-phase studies (e.g. exploratory studies of multiple products within a single class or studies that employ a common route of administration) in order to develop and implement a robust long-term safety monitoring protocol would be useful. Address the Complexities involved in Dose Exploration Recognizing the complications of performing dose explorations with CGT products, the agency suggests that in certain cases, limiting dose exploration to determine the biologically active or optimal effective dose would suffice. Further, since there may be significant practical limits on the dose of the product that can be produced or delivered, investigators may focus on characterizing the safety profile of the feasible dose or doses, rather than finding the Maximum Tolerated Dose (MTD). Given the uniqueness of CGT products it would be helpful if the agency could clarify how the agency might accommodate for the fact that MTD and biologically active dose for these products may sometimes vary for each patient and therefore efficacy and toxicity may vary as well. For certain CGT products a standard feasible dose may never be achieved (E.g. Chimeric Antigen Receptor T-Cell therapy). In such cases it would be helpful if the agency can accommodate for variable dosing of the study population by the sponsor. This in turn leads to another issue- if base-dosing parameters are established such that different subpopulations are to be treated with different doses; it would be helpful if the agency could clarify whether multi-dosing protocols would be permissible in later-stage study designs. It would also be useful if the agency could provide examples of what kinds and levels of data should be collected in early stage studies to provide the scientific rationale to establish multiple dosing regimens in later studies of these products. For certain CGT products MTD may never be achieved which may impact the agency (and sponsor s) assessment of later stage dosing studies. It would be helpful if the agency could explicitly state whether failure to establish a MTD for these products in early-stage studies will constitute a problem in subsequent studies. Agency notes that for life-threatening diseases, such as cancer, some toxicities may be acceptable. It would be helpful if the agency could elaborate or give examples of acceptable toxicities. Further, it would be helpful if the agency could clarify if toxicities would be acceptable if they are anticipated and/or can be managed.
4 Page 4 Clarify the Process of Product Activity Assessments Agency notes that a secondary objective of early-phase studies is to obtain preliminary assessments of product activity that could suggest potential efficacy. Given the complicated nature and mechanism of action of some CGT products, it would be helpful if the agency could clarify how it will distinguish between product activity, bioavailability and product efficacy. This is especially pertinent to products that may have long-term beneficial effects but have no immediate signs of benefit for the patient or even display short term toxic effects in the patient. It would also be helpful if the agency can clarify whether a sponsor is required to collect and/or submit these data even if preliminary product activity cannot be determined and/or distinguished in early studies. In case the agency does require this data to be submitted, it should clarify what exactly constitutes product activity data and whether alternate or surrogate data points indicative of product activity can be substituted. Further, in these cases, it would be helpful if the agency can clarify whether early study data can be retrospectively analyzed to establish and validate surrogate markers/endpoints in subsequent studies. Choosing an Appropriate Study Population The draft notes that for most CGT trials, the risk-benefit profile is not acceptable for healthy volunteers. However, it is inevitable that situations will arise where these products will warrant testing in a healthy volunteer population. Therefore, the agency could give examples of cases wherein healthy volunteers can be enrolled to aid sponsors. The Agency acknowledges that patients with severe or advanced stage disease are more likely to accept the risks inherent in experimental therapies and therefore more likely to enroll in trials. However, the draft suggests that patients with less advanced or more moderate disease may be more appropriate. The draft also suggests that co-morbidities in patients with advanced disease may complicate data interpretation and that patient enrollment must be done keeping in mind the ultimate target population for the treatment. Given the above, it would help if the agency could give examples or specify situations wherein enrollment of patients with less severe disease would be appropriate. Often, early-phase studies can be exploratory with a goal of identifying the ultimate target population profile. In such cases, the sponsor would pursue studies in a variety of populations in early stages. Therefore, it would be helpful if the agency could elaborate on how such an exploratory study may be pursued. The draft states that the decision about the severity of disease to be studied in an early-phase trial should be made only after considering the estimated nature and magnitude of the risks to the subjects, and the implications of those risks, for various stages or severity of the disease. Further, in considering and balancing risk-benefit profile, the potential for individual benefit should be balanced against an assessment of overall risk-benefit. In early-phase studies, the complete risk-benefit profile of the treatment is still not completely understood. Given that, it
5 Page 5 would be helpful for the Agency to provide examples wherein individual benefits may outweigh overall risks. The Agency cautions that risk of the administration procedure (for invasive or otherwise risky administration) is also an aspect of the overall treatment that needs to be evaluated. Given that it may not be advisable to administer a placebo using an invasive or otherwise risky procedure; it would help sponsors if the agency could elaborate on how it will parse out the risk posed by the administration procedure versus the risk posed by the treatment itself. Clarify appropriate use of Stopping Rules Due to the uncertain and high-risk nature of CGT treatments, the agency recommends including stopping rules in early phase study protocols. Stopping rules may not necessarily terminate a trial and well-designed stopping rules may allow sponsors to assess and address risks identified as the trial proceeds, and to amend the protocol to mitigate such risks or to assure that risks to patients remains reasonable. It would help if the agency could detail how data gathered to stop the study can be used to amend the protocol and/or be analyzed to assure that risk to patients is reasonable. Integrating validation procedures for large scale production Early phase studies with CGT products involve small batch testing. However, in order to proceed to the next phase of testing, production must be scaled up. Large scale manufacturing of CGT products can be complicated as cellular potency, ex vivo expansion etc. can vary between batches. Therefore, the process for large scale production should be validated such that the quality of the product is consistent and is not compromised during scale up operations. Consequently, if the validation process for large scale production could be integrated into early phase study design, the sponsor would be prepared to advance to the next stage of the study without undue delay. Hence, it would be helpful if the agency could provide some guidance on how sponsors may seek to validate the process for scaling up manufacture of these products during early phase studies. Further, the agency, given its expertise and experience with these products and the problems that arise during large scale production, could also provide sponsors with guidance regarding common potential production problems to be alert to and the means to alleviate the same. The AACR commends the FDA for its commitment to incorporating scientific advances into its regulatory framework. The AACR is pleased to extend its resources and broad expertise to the FDA as the Agency further refines its guidance for early-phase studies of cellular and gene therapy products to support the approval of human drugs and biological products as well as other critical issues. If you have any further questions or require follow up, please contact Rasika Kalamegham, PhD, Senior Science Policy Analyst at or
6 Page 6 Sincerely, Frank McCormick, Ph.D., F.R.S. Chair, Regulatory Science & Policy Subcommittee Margaret Foti, Ph.D., M.D. (h.c.) Chief Executive Officer
Challenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
Overview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
Clinical trials preclinical requirements. Clinical trials - legislation
Clinical trials preclinical requirements Mikael Andersson, PhD Senior Expert Medical Products Agency, Sweden Tallinn 9/10 2009 Clinical trials - legislation Directive 2001/20/EC Clinical trial directive
The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd.
The Clinical Trial Protocol Guide 2011 BioStrategics Consulting Ltd. BioStrategics Consulting Ltd THE CLINICAL TRIAL PROTOCOL The clinical trial protocol to test one s product, to confirm or reject a specific
Rare Diseases: Common Issues in Drug Development Guidance for Industry
Rare Diseases: Common Issues in Drug Development Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
Guideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
Guidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
From The Lab To Your Medicine Cabinet:
From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process
Not All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
The Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
Sheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
Guidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed
TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?
TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? PD Dr. med. Thomas Sudhop Bundesinstitut für Arzneimittel, Bonn Bundesinstitut für Arzneimittel IMP
Session 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
Operational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405
Guidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
Expanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
Quality Considerations for Breakthrough Therapies-FDA Perspective
Quality Considerations for Breakthrough Therapies-FDA Perspective DIA June 17, 2014 Ramesh K. Sood, Ph.D. Acting Division Director and Angelica Dorantes, Ph.D. xxx ONDQA/OPS/CDER/FDA 1 Background Outline
Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
Public Policy Statement: Clinical Trial Ethics
Public Policy Statement: Clinical Trial Ethics Purpose As a global healthcare company, Merck's role is first and foremost to discover, develop and provide innovative products and services that save and
New Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18 th WMA General Assembly Helsinki, Finland, June 1964 and amended by
NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety,
NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate
Overview of Drug Development
Overview of Drug Development Namrata Bahadur Head of Clinical Development & Medical Affairs Emerging Growth Markets 17 th 21 st March, Bangkok 2008 Novartis The information within this presentation is
ICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
CenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
Guidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Overview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
Research on Research: Learning about Phase 1 Trials
CLINICAL CASE STUDY SERIES Research on Research: Learning about Phase 1 Trials Phases of clinical trial investigation are described in some detail in the Code of Federal Regulations. Phase 1 is described
Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
Draft Guidance for Industry Premarketing Risk Assessment
Draft Guidance for Industry Premarketing Risk Assessment [Docket Number 2004D-0187] Submitted to the U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
exactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune
Clinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group
Clinical Trial Protocol Development Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group Objectives The clinical trial protocol is the heart of any
Quality and Safety Evaluation of Gene Therapy Products in Japan
Quality and Safety Evaluation of Gene Therapy Products in Japan Review Mechanism for Gene Therapy in Japan The review mechanism for gene therapy in Japan was partially amended to simplify the necessary
SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015
THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background
Guidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies
OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies Innovative Drug Research and Development in Russia 2012 OCT: CRO in Russia, Central and Eastern Europe Russian Innovative
Glossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
Waiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
Dec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
CTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
Advancing research: a physician s guide to clinical trials
Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer
Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO
Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced
Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award
Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award The Cooley s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and
Safety Assessment for IND Safety Reporting Guidance for Industry
Safety Assessment for IND Safety Reporting Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Waiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
Bayesian Phase I/II clinical trials in Oncology
Bayesian Phase I/II clinical trials in Oncology Pierre Mancini, Sandrine Micallef, Pierre Colin Séminaire JEM-SFES - 26 Janvier 2012 Outline Oncology phase I trials Limitations of traditional phase I designs
ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
Guidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution
CAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
The Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
Roles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
Clinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
Testing Services for Large Molecule Drug Development
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA
PharmaSUG 2014 Paper CP07 Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA ABSTRACT In the biopharmaceutical
Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics
Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
ADDPLAN DF: Designing More Accurate Dose Escalation Studies in Exploratory Drug Development. An ICON White Paper
ADDPLAN DF: Designing More Accurate Dose Escalation Studies in Exploratory Drug Development An ICON White Paper Executive Summary The determination of the maximum tolerated dose (MTD) level is a critical
Participating in Alzheimer s Disease Clinical Trials and Studies
Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
Best Practices in Clinical Research Protocol Writing: Eight tips from an IRB member
Best Practices in Clinical Research Protocol Writing: Eight tips from an IRB member 02/02/16 description The clinical research protocol is the single most important document to ensure critical elements
Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14)
Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14) Documents to be submitted for grant of permission to conduct BA/BE studies in Human Subjects/Patients
Medicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols
Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER
Patient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
A Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
Drug Development Process
Drug Development Process Original Arthur: Addie D. Anderson CRB Consulting Engineers, Inc. Overview Important milestones establishing our current system of regulations Step-by-step overview of the drug
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
Nova Southeastern University Institutional Review Board Policies and Procedures
Page 1 of 14 Purpose: To establish policy with respect to the emergency use of unapproved drugs and biologics. Definitions: 1. IRB approval means the determination of the IRB that the research has been
WMA Declaration of Helsinki - Ethical
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the: 29th WMA General
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies
PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global